Relay Therapeutics, Inc. Price & Performance (RLAY)

Relay Therapeutics has announced its third round of layoffs in a year, eliminating about 70 positions and reducing its workforce to under 200. The move is expected to cut the company's annual research budget by 75% as Relay prepares for a pivotal Phase III breast cancer trial. These cuts reflect ongoing financial pressures and industry-wide realignments.12

Despite a dramatic decline in Relay Therapeutics’ share price over the past year, analysts remain largely positive, citing the company’s promising breast cancer drug candidate and robust cash reserves. Recent upward revisions to earnings estimates and a consensus 'Moderate Buy' rating highlight continued confidence in Relay's clinical and financial positioning.32

Relay Therapeutics is advancing a late-stage breast cancer trial and exploring new drug combinations, bolstered by strong cash reserves and ongoing R&D. While revenue has declined sharply, the company’s strategic pipeline developments and financial cushion position it among stocks anticipated to rebound significantly in value.45